Thanks to all who came out to hear important policy & study updates and about the use of DoxyPEP for STI prevention in San Francisco.

The program agenda included an update on drug overdose prevention and advocacy efforts in San Francisco by Laura Thomas (SFAF). Dr. Anne Luetkemeyer (UCSF) got to the “heart” of the matter with an update on a consequential study (REPRIEVE) focused on preventing cardiovascular disease among people living with HIV and how this will change clinical practice. We also heard an update on CDC and SFDPH guidelines for DoxyPEP by Dr. Stephanie Cohen (SFDPH) and a presentation of initial data and analysis on DoxyPEP use in SF for STI prevention.

Linked here are slides from the meeting.

Also, as mentioned during the meeting here is a link to a recent webinar hosted by The Choice Agenda –  “DoxyPEP Implementation – All Systems Go?” A discussion on the rollout of Doxycycline as STI PEP for helping gay, bisexual, and other men who have sex with men and transgender women reduce bacterial STIs, including gonorrhea, chlamydia, and syphilis.